Burning Rock Biotech, Ltd.
Headquartered in China and founded in 2014, Burning Rock Biotech, Ltd., whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology.
Burning Rock Biotech's business consists of (i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and (ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
Location of Key Operations
Ernst & Young LLP
IPO (June 12, 2020)